###begin article-title 0
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis
###end article-title 0
###begin p 1
Conceived and designed the experiments: PC JF. Performed the experiments: PC RL. Analyzed the data: PC MLG CA RM JdCC CBI JB VMG JL EC MGB JF. Contributed reagents/materials/analysis tools: JL. Wrote the paper: PC MLG CA RM JF.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
KRAS mutations in colorectal cancer primary tumors predict resistance to anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody therapy in patients with metastatic colorectal cancer, and thus represent a true indicator of EGFR pathway activation status.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 467 471 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 651 655 651 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 816 820 816 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1128 1132 1128 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1266 1270 1266 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1438 1442 1438 1442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
###xml 611 619 <span type="species:ncbi:9606">Patients</span>
###xml 902 910 <span type="species:ncbi:9606">patients</span>
###xml 1018 1026 <span type="species:ncbi:9606">patients</span>
###xml 1212 1220 <span type="species:ncbi:9606">patients</span>
###xml 1302 1310 <span type="species:ncbi:9606">patients</span>
###xml 1417 1425 <span type="species:ncbi:9606">patients</span>
###xml 1505 1513 <span type="species:ncbi:9606">patients</span>
KRAS mutations were retrospectively studied using polymerase chain reactions and subsequent sequencing of codons 12 and 13 (exon 2) in 110 patients with metastatic colorectal tumors. These studies were performed using tissue samples from both the primary tumor and their related metastases (93 liver, 84%; 17 lung, 16%). All patients received adjuvant 5-Fluorouracil-based polychemotherapy after resection of metastases. None received anti-EGFR therapy. Mutations in KRAS were observed in 37 (34%) of primary tumors and in 40 (36%) of related metastases, yielding a 94% level of concordance (kappa index 0.86). Patients with primary tumors possessing KRAS mutations had a shorter disease-free survival period after metastasis resection (12.0 vs 18.0 months; P = 0.035) than those who did not. A higher percentage of KRAS mutations was detected in primary tumors of patiens with lung metastases than in patients with liver metastases (59% vs 32%; p = 0.054). To further evaluate this finding we analyzed 120 additional patients with unresectable metastatic colorectal cancer who previously had their primary tumors evaluated for KRAS mutational status for clinical purposes. Separately, the analysis of these 120 patients showed a tendency towards a higher degree of KRAS mutations in primary tumors of patients with lung metastases, although it did not reach statistical significance. Taken together the group of 230 patients showed that KRAS was mutated significantly more often in the primary tumors of patients with lung metastases (57% vs 35%; P = 0.006).
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Our results suggest a role for KRAS mutations in the propensity of primary colorectal tumors to metastasize to the lung.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 140 143 140 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Jemal1">[1]</xref>
###xml 349 352 349 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Penna1">[2]</xref>
###xml 543 546 543 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Fong1">[3]</xref>
###xml 1049 1052 1049 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Lockhart1">[4]</xref>
###xml 1054 1057 1054 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Jean1">[5]</xref>
###xml 1235 1238 1235 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Grandal1">[6]</xref>
###xml 1401 1404 1401 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Fransen1">[7]</xref>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
###xml 422 430 <span type="species:ncbi:9606">patients</span>
###xml 512 520 <span type="species:ncbi:9606">patients</span>
###xml 568 576 <span type="species:ncbi:9606">patients</span>
###xml 693 701 <span type="species:ncbi:9606">patients</span>
Colorectal cancer (CRC) is one of the most common malignancies and one of the leading causes of cancer-related death in developed countries [1]. Distant metastasis is the main cause of death in CRC patients. Depending on the stage of the primary tumor, liver metastases occur in 20% to 70% of patients, and lung metastases in 10% to 20% of patients [2]. Surgical resection remains the only potentially curative option for patients with metastatic CRC. However, curative resection is possible in less than 25% of patients with stage IV disease [3], and less than 5% of patients with unresectable metastatic CRC are alive after 5 years. Major efforts are being made to improve the prognosis for patients with metastatic CRC, especially in the development of new therapeutic strategies. The Epidermal Growth Factor Receptor (EGFR) signalling pathway has become a key target for therapeutic intervention because two monoclonal antibodies directed against EGFR have become important tools in the management of advanced disease: cetuximab and panitumumab [4], [5]. EGFR activates proliferative and antiapoptotic signalling pathways, such as the phosphatidylinositol 3' kinase/Akt and Ras/Raf/mitogen-activated protein kinase (MAPK) pathways [6]. Aberrant activation of the EGFR pathway in CRC could be caused by either EGFR overexpression or mutational activation of downstream elements of the EGFR pathway [7].
###end p 9
###begin p 10
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 264 267 264 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Fransen1">[7]</xref>
###xml 269 272 269 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Barbacid1">[8]</xref>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 350 353 350 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Wong1">[9]</xref>
###xml 359 363 359 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 412 416 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Vogelstein1">[10]</xref>
###xml 463 467 463 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 562 566 562 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Santini1">[11]</xref>
###xml 568 572 568 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-EtienneGrimaldi1">[12]</xref>
###xml 627 631 627 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 747 751 747 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Karapetis1">[13]</xref>
###xml 753 757 753 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Amado1">[14]</xref>
###xml 792 796 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 976 980 976 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1010 1014 1010 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Lievre1">[15]</xref>
###xml 1049 1053 1049 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-EtienneGrimaldi1">[12]</xref>
###xml 1137 1141 1137 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1272 1276 1272 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1384 1388 1384 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Andreyev1">[16]</xref>
###xml 718 726 <span type="species:ncbi:9606">patients</span>
###xml 850 858 <span type="species:ncbi:9606">patients</span>
###xml 1190 1198 <span type="species:ncbi:9606">patients</span>
KRAS is a small GTP-binding protein that transduces signals from activated cell surface receptors to the nucleus. Constitutive KRAS activation by point mutations in codons 12 and 13 of exon 2 has been described as an important cause of EGFR pathway overactivation [7], [8]. The incidence of KRAS mutations in colorectal tumors ranges from 35% to 45% [9], and KRAS mutations seem to occur early in carcinogenesis [10]. Accordingly, a high degree of concordance in KRAS mutational status between primary tumors and their related liver metastases has been reported [11], [12]. Recent data have demonstrated an association between KRAS mutational status in the primary tumor and resistance to cetuximab and panitumumab in patients with metastatic CRC [13], [14]. However, the association between KRAS mutational status and prognosis is controversial for patients with metastatic CRC that have not been treated with anti-EGFR antibodies, with some studies reporting a link between KRAS mutations and poor prognosis [15] and some reporting no association [12]. Interestingly, the largest multicentre study conducted on the association between KRAS mutation and prognosis, which included 3439 CRC patients, showed that the presence of a glycine-to-valine mutation at codon 12 of KRAS significantly decreased progression-free and overall survival rates irrespective of the treatment received [16].
###end p 10
###begin p 11
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
We sought to elucidate the correlation between KRAS mutational status, clinicopathologic factors, prognosis, metastasis pattern and concordance between the primary tumor and matched metastases in patients with metastatic CRC.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Characteristics
###end title 13
###begin p 14
###xml 121 125 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 665 672 665 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008199-t001">Table 1</xref>
###xml 468 476 <span type="species:ncbi:9606">patients</span>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
###xml 512 519 <span type="species:ncbi:9606">patient</span>
###xml 538 543 <span type="species:ncbi:9606">women</span>
###xml 551 554 <span type="species:ncbi:9606">men</span>
We retrospectively analysed specimens from 110 primary tumors and 110 corresponding metastatic sites for the presence of KRAS mutations in codons 12 and 13. The most common metastatic site was the liver, which was the metastatic site in 93 samples (84%). The lung was the metastatic site in the remaining 17 samples (16%). Metastases appeared synchronously with the primary lesion in 57 cases and metachronously in 53 cases. The primary tumor site was the colon in 79 patients and the rectum in 31 patients. The patient group included 32 women and 78 men. Median age was 64 years (29-86). All cancers were adenocarcinomas and were graded according to WHO criteria (Table 1).
###end p 14
###begin title 15
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics.
###end title 15
###begin title 16
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
KRAS Mutations and Histopathological Parameters
###end title 16
###begin p 17
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 252 256 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 357 361 357 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 419 423 419 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
Mutations in KRAS were detected in 37 (34%) primary tumors and in 40 (36%) related metastatic lesions, with a 94% grade of concordance between primary and metastatic samples (kappa index 0.86). Discordance was observed in 7 patients. Five patients had KRAS mutations in the metastases (four with liver metastases and one with lung metastases) and wild type KRAS in the primary tumor, whereas the two other patients had KRAS mutations only in the primary tumor (1 with liver metastases and 1 with lung metastases).
###end p 17
###begin p 18
###xml 234 241 234 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008199-t002">Table 2</xref>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
There was little variance between the mutation type present in the primary tumor and its metastases: all but four patients had the same mutation in both the primary and the metastatic samples. The types of mutations are summarized in Table 2. There was no relationship between the type of mutations and any clinicopathological parameter.
###end p 18
###begin title 19
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Codon distribution of specific KRAS mutations.
###end title 19
###begin p 20
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 92 99 92 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008199-t003">Table 3</xref>
No associations between KRAS mutations and histopathological characteristics were observed (Table 3).
###end p 20
###begin title 21
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Relationship between KRAS mutational status and tumoral variables measured in primary tumors.
###end title 21
###begin title 22
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
KRAS Mutations and Prognosis
###end title 22
###begin p 23
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 214 218 214 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 304 312 304 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008199-g001">Figure 1</xref>
###xml 426 430 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 508 515 508 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008199-t004">Table 4</xref>
###xml 572 576 572 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 596 604 596 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008199-g001">figure 1</xref>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
Our results show lower rates of disease-free survival after metastasis resection in patients whose tumors had a KRAS point mutation in the primary tumor; median disease-free survival was 12 months in patients with KRAS mutations in their tumors and 18 months in those without KRAS mutations (p = 0.035) (Figure 1). The multivariate analysis showed that the most significant independent predictor for disease-free survival was KRAS mutational status (multivariate HR = 2.068; 95% CI, 1.136-3.766, P = 0.018) (Table 4). No association was found between overall survival and KRAS mutational status (figure 1).
###end p 23
###begin title 24
Kaplan-Meier survival analysis.
###end title 24
###begin p 25
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Curves for disease-free survival (A) and overall survival (B) according to KRAS status.
###end p 25
###begin title 26
Multivariate disease-free survival analysis.
###end title 26
###begin p 27
Abbreviations: HR: Hazard Ratio. CI: Confidence Interval.
###end p 27
###begin title 28
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
KRAS Mutations and Metastatic Site
###end title 28
###begin p 29
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 236 240 236 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 511 515 511 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 655 659 655 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 713 720 713 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008199-t005">Table 5</xref>
###xml 762 766 762 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 963 967 963 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1186 1190 1186 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1434 1438 1434 1438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1734 1738 1734 1738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1870 1877 1870 1877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008199-t006">Table 6</xref>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
###xml 442 450 <span type="species:ncbi:9606">patients</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
###xml 673 681 <span type="species:ncbi:9606">patients</span>
###xml 845 853 <span type="species:ncbi:9606">patients</span>
###xml 916 924 <span type="species:ncbi:9606">patients</span>
###xml 1059 1067 <span type="species:ncbi:9606">patients</span>
###xml 1222 1230 <span type="species:ncbi:9606">patients</span>
###xml 1407 1415 <span type="species:ncbi:9606">patients</span>
###xml 1474 1482 <span type="species:ncbi:9606">patients</span>
###xml 1593 1601 <span type="species:ncbi:9606">patients</span>
###xml 1648 1656 <span type="species:ncbi:9606">patients</span>
###xml 1770 1778 <span type="species:ncbi:9606">patients</span>
Mutated KRAS was detected in a higher proportion of primary tumors of patiens with lung metastases than in those with liver metastases (59% vs 32%, P = 0.054). When stratified by origin of the primary tumor (colon or rectum), of the 10 KRAS-mutated primary tumors of patients with lung metastases, 7 were colonic in origin (70%) whereas the other 3 originated in the rectum (30%). Statistical analysis revealed that colonic primary tumors of patients with lung metastases were significantly more likely to have KRAS mutations than colonic primary tumors of patients with hepatic metastases (P = 0.046), whereas rectal primaries had a similar frequency of KRAS mutations in patients with lung or liver metastasis (Table 5). To further investigate the presence of KRAS mutations as a predictor of lung metastasis, we also examined a series of 120 patients with unresectable metastatic CRC. The primary tumors of these patients had been analysed for the presence of KRAS mutations by a central laboratory prior to cetuximab administration. Of the 120 metastatic patients, 86 had liver metastases and 34 had lung metastases. In addition, there was a tendency towards a higher proportion of KRAS mutations in primary tumors of patients with lung metastases than in those with liver metastases, although it did not reach statistical significance (56% vs 38%; P = 0.1027). When we analysed the whole series of 230 patients, the frequency of KRAS mutations in the primary tumors of patients with lung metastases was significantly higher as compared with liver metastases (57% vs 35%; P = 0.006). When patients were stratified by primary tumor origin, only patients with colonic primary tumor origin showed a significantly higher frequency of KRAS mutations in primary tumors of patients with lung metastases as compared with those with liver metastases (59% vs 34%; P = 0.019) (Table 6).
###end p 29
###begin title 30
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
KRAS mutational status in the primary tumor according to the metastatic site (series of 110 patients).
###end title 30
###begin title 31
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
KRAS mutational status in the primary tumor according to metastatic site (whole series of 230 patients).
###end title 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Tabernero1">[17]</xref>
###xml 345 349 345 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 430 434 430 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 491 495 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Karapetis1">[13]</xref>
###xml 511 515 511 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Amado1">[14]</xref>
###xml 573 577 573 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 747 751 747 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 949 953 949 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1004 1008 1004 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Vogelstein1">[10]</xref>
###xml 1156 1160 1156 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Oliveira1">[18]</xref>
###xml 1229 1233 1229 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1271 1274 1271 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Wong1">[9]</xref>
###xml 1343 1347 1343 1347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1424 1428 1424 1428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Santini1">[11]</xref>
###xml 1430 1434 1430 1434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-EtienneGrimaldi1">[12]</xref>
###xml 1436 1440 1436 1440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Artale1">[19]</xref>
###xml 1557 1561 1557 1561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1757 1761 1757 1761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1836 1840 1836 1840 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 2069 2073 2069 2073 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 2659 2663 2659 2663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Rama1">[20]</xref>
###xml 2851 2855 2851 2855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 3120 3124 3120 3124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 3252 3256 3252 3256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 3505 3509 3505 3509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 3602 3606 3602 3606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 3797 3801 3797 3801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 4204 4208 4204 4208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 4544 4548 4544 4548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 4703 4707 4703 4707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 4775 4779 4775 4779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Oudejans1">[21]</xref>
###xml 4827 4831 4827 4831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 5111 5115 5111 5115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
###xml 694 702 <span type="species:ncbi:9606">patients</span>
###xml 1477 1485 <span type="species:ncbi:9606">patients</span>
###xml 2424 2432 <span type="species:ncbi:9606">patients</span>
###xml 2794 2802 <span type="species:ncbi:9606">patients</span>
###xml 2887 2895 <span type="species:ncbi:9606">patients</span>
###xml 3156 3164 <span type="species:ncbi:9606">patients</span>
###xml 3270 3278 <span type="species:ncbi:9606">patients</span>
###xml 3425 3433 <span type="species:ncbi:9606">patients</span>
###xml 3592 3600 <span type="species:ncbi:9606">patients</span>
###xml 3773 3781 <span type="species:ncbi:9606">patients</span>
###xml 3854 3862 <span type="species:ncbi:9606">patients</span>
###xml 3898 3906 <span type="species:ncbi:9606">patients</span>
###xml 4074 4082 <span type="species:ncbi:9606">patients</span>
###xml 4148 4156 <span type="species:ncbi:9606">patients</span>
###xml 4240 4248 <span type="species:ncbi:9606">patients</span>
###xml 5046 5054 <span type="species:ncbi:9606">patients</span>
###xml 5153 5161 <span type="species:ncbi:9606">patients</span>
The prognosis for patients with metastatic CRC has improved since the introduction of novel therapeutic agents such as anti-EGFR antibodies [17]. This therapeutic success highlights the importance of counteracting the EGFR pathway to control advanced disease. Aberrant activation of the EGFR pathway sometimes occurs by mutational activation of KRAS. Recent clinical trials have shown that the presence of activating mutations in KRAS identifies patients who are non-responders to cetuximab [13] or panitumumab [14]. In fact, based on these results, mutational analysis of KRAS is now recommended by The US Food and Drug Administration (FDA) prior to cetuximab or panitumumab administration to patients with metastatic CRC. Mutational analysis of KRAS is commonly performed on the primary tumor because it is often the only available tissue. Moreover, the value of performing this analysis on the primary tumor is further supported by evidence that KRAS point mutations occur early in CRC carcinogenesis [10]. However, recent data have demonstrated an increased frequency of mutations in lymph node metastases as compared with their related primary tumors [18]. With this in mind, the potential need for rebiopsy and analysis of KRAS in the metastases has been suggested [9]. Other recent studies have reported a high degree of concordance in KRAS mutational status between primary tumors and their related liver metastases [11], [12], [19]. The results from our series of 110 patients are in complete agreement with these reports, both in the frequency of KRAS mutations in primary tumors, which was 34% in our study, and in the high degree of concordance between primary tumors and their related metastases. All of these findings confirm that analysis of KRAS mutational status in the primary tumor is an adequate surrogate marker of KRAS mutational status in metastases. Our study includes an analysis of both liver and lung metastases. As far as we know, this is the first study to analyse primary colorectal tumors and their related lung metastases and correlated KRAS mutational status based on both clinicopathological features and survival data. The liver and the lung are both common sites of CRC metastases. Secondary to their respective anatomical blood vessel distribution, lung metastases are more common with rectal cancers and liver metastases are more frequent with colon cancers. However, some colon cancer patients experience lung metastases without evidence of previous liver metastases. This unexplained anatomical pattern of metastasis, observed with increasing frequency due to more accurate diagnoses based on highly efficient CT scans [20], suggests a peculiar biological mechanism of carcinogenesis or a special susceptibility of the lung parenchyma to tumors in these patients. Our results demonstrate a higher percentage of KRAS mutations in primary tumors of patients with lung metastases as compared with those with liver metastases (59% vs 32%). Moreover, when we stratified our results based on the primary tumor site, only tumors of colonic origin had a significantly higher frequency of KRAS mutations in primary tumors of patients with lung metastases. By contrast, rectal primary tumors showed a similar frequency of KRAS mutations in patients with lung metastases than in those with liver metastases. To further analyze this finding we studied an independent series of primary tumors from patients with unresectable metastatic CRC and examined the relationship between KRAS mutational status in the primary tumor and the site of tumor metastasis. In these patients, KRAS mutational status in the primary tumor was previously analysed for clinical purposes prior to cetuximab administration. Statistical analysis of the whole series (230 patients) revealed that KRAS is more frequently mutated in the primary tumors of patients with lung metastases compared with patients with liver metastases (57% vs 35%, P = 0.006). When the results are stratified according to the site of the primary tumor, the analysis we performed including all 230 patients confirmed the results we obtained with the smaller sample of 110 patients: that the significantly increased frequency of KRAS mutations in primary tumors in patients with lung metastases was restricted to those primary tumors that originated in the colon. This finding suggests that EGFR pathway activation may allow colonic tumor cells to nest preferentially in the lung parenchyma avoiding an initial step of liver metastasis. A previous study that evaluated KRAS status in primary colorectal tumors and non-matched liver and lung metastases showed concordant results with our study and revealed a higher incidence of KRAS mutations in lung metastases than in liver metastases (57% vs 50%) [21]. However, in that study, a major difference in KRAS activation between the primary and metastatic tumors could have been masked by the absence of related primary and metastatic samples. This finding has clinical importance because it may allow the identification of patients who are more likely to develop lung metastases based on KRAS analysis of the primary tumor. These patients should potentially receive a more thorough clinical workup, including a thorax scan, which is not always included in the standard clinical workup for CRC.
###end p 33
###begin p 34
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 467 471 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 660 664 660 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Andreyev1">[16]</xref>
###xml 803 807 803 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 830 834 830 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-EtienneGrimaldi1">[12]</xref>
###xml 866 870 866 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1012 1016 1012 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1080 1084 1080 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1186 1190 1186 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1348 1352 1348 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1514 1518 1514 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1770 1774 1770 1774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 723 731 <span type="species:ncbi:9606">patients</span>
###xml 998 1006 <span type="species:ncbi:9606">patients</span>
###xml 1562 1570 <span type="species:ncbi:9606">patients</span>
###xml 1898 1906 <span type="species:ncbi:9606">patients</span>
Our results also show that the presence of KRAS mutations is an independent prognostic factor in the prediction of disease-free survival (reaching statistical significance). Constitutive activation of the Ras-Raf-MAP-kinase pathway is known that confers proliferative and disseminative advantage to tumor cells. However, controversy exists regarding the prognostic role of KRAS mutations in CRC. The biggest clinical trial designed to analyse the prognostic value of KRAS status was the RASCAL study, which showed that a glycine-to-valine mutation in codon 12 increased the risk of recurrence and death by 30%, irrespective of the type of therapy administered [16]. However, a recent study performed with a small number of patients did not reproduce this result and did not demonstrate any influence of KRAS mutations on survival [12]. Thus, the prognostic value of KRAS mutational status remains controversial. Our results are in agreement with the RASCAL study and suggest a poorer prognosis for patients with KRAS-mutated primary tumors, with a significant association between KRAS mutational status and a shorter disease-free survival. By contrast, no association was found between KRAS status and overall survival. This can be explained by the administration of chemotherapy after relapse. The multivariate analysis shows that the presence of KRAS mutations is an independent prognostic factor in the prediction of disease-free survival (reaching statistical significance), thus highlighting the relevance of KRAS mutational status in the present series of patients. Regarding a potential influence of the mutation type on prognosis, our results, in contrast to the RASCAL study, show no differences with respect to mutation type. Of course, the potential value of KRAS mutations as a prognostic factor shown in this study must be taken cautiously, due to the limited and particular series of patients evaluated.
###end p 34
###begin p 35
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
In summary, our findings suggest that KRAS-mutated primary CRC tumors tend to metastasize more frequently to the lung and are associated with a higher rate of relapse after resection of the metastases. This finding could be of clinical interest with regard to the follow-up of patients with KRAS-mutated primary CRC tumors, and thus merits further investigation.
###end p 35
###begin title 36
Methods
###end title 36
###begin title 37
Ethics Statement
###end title 37
###begin p 38
###xml 106 114 <span type="species:ncbi:9606">patients</span>
The Ethical Committee of the La Paz University Hospital in Madrid, Spain, approved the current study. All patients were informed and consented in writing.
###end p 38
###begin title 39
###xml 9 17 <span type="species:ncbi:9606">Patients</span>
Eligible Patients
###end title 39
###begin p 40
###xml 616 620 616 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1989 1996 1989 1996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008199-t001">Table 1</xref>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
###xml 259 267 <span type="species:ncbi:9606">patients</span>
###xml 1885 1893 <span type="species:ncbi:9606">Patients</span>
One hundred and ten patients with metastatic CRC with available primary tumor and paired metastatic specimens were selected from a database of patients from La Paz University Hospital in Madrid. This study was approved by the hospital's ethics committee. The patients were diagnosed with metastatic CRC between 1997 and 2007. Of the 326 cases of metastatic CRC diagnosed during this time period, study inclusion was limited to those with curative metastasis resection, available tissue specimens (both from the primary tumor and related metastases), available follow-up data after metastasis removal, and successful KRAS mutational status analysis. The median follow-up after surgery was 10 months (range: 0-144 months). All tumors were histologically confirmed to be colorectal adenocarcinomas. In addition, pathology reports included information on the tumor site, tumor size, pathological stage, tumor grade (based on the degree of histological differentiation), presence or absence of lymph node metastasis, tumor growth pattern (infiltrative or expansive), presence or absence of vascular and lymphatic invasion, and presence or absence of tumor lymphocytic infiltrates. The primary stage has been classified into 4 stages according to WHO criteria. The number and size of metastases were determined by diagnostic imaging, either with abdominal and pelvic computed tomography or with magnetic resonance imaging. Metastasis resection was performed when there was no evidence of extra-hepatic disease, ensuring enough functioning residual liver after resection (approximately 25%-30% of normal liver volume) to provide hepatic function postoperatively, adjusted based on existing liver disease such as cirrhosis or hepatitis. Metastatic samples were obtained from either the liver or the lung. These metastatic samples were obtained from either synchronous or metachronous lesions. Patients received one of three different chemotherapy regimens after metastasis resection (described in Table 1).
###end p 40
###begin p 41
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 422 426 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 523 527 523 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 744 748 744 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
###xml 440 448 <span type="species:ncbi:9606">patients</span>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
After the discovery of the discordance between KRAS mutations in liver and lung metastases, an additional series of 128 metastatic CRC patients (86 with liver metastasis, 34 with lung metastasis, and 8 with other types of mutations (these last 8 patients were not included in the statistical analysis) from La Paz Hospital were prospectively collected between 2007 and 2009, to validate the hypothesis of a higher rate of KRAS mutations in patients with lung metastases. These patients had unresectable metastatic disease. KRAS status in the primary tumor was determined for clinical purposes prior to cetuximab administration. The only clinicopathological data collected for these patients was the site of the primary tumor (colon vs rectum). KRAS analysis was performed using the TheraScreen K-RAS mutation test kit (DXS Diagnostic Innovations) by an independent central laboratory in Madrid, following the manufacturer's instructions.
###end p 41
###begin title 42
DNA Extraction
###end title 42
###begin p 43
###xml 152 159 <span type="species:ncbi:9606">patient</span>
Paraffin-embedded primary tumor specimens (n = 110) and metastatic tumor specimens (n = 110) containing at least 70% tumor cells were selected for each patient. Tissue blocks were macro-dissected using a safety blade when samples were less than 70% enriched with tumoral cells. Metastatic tumors were located in the liver (n = 93) and the lung (n = 17). DNA was isolated from 15 7-microm paraffin sections. Tissue sections were deparaffinated with xilol and rehydrated with downgraded alcohols. Tissues were digested with Proteinase K, and DNA was isolated using a MasterPure DNA Kit (Epicentre, Biotechnologies). In each instance, negative controls were amplified by PCR and included in the experiment.
###end p 43
###begin title 44
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
KRAS Mutation Analysis
###end title 44
###begin p 45
###xml 203 207 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008199-Lievre1">[15]</xref>
A polymerase-chain reaction (PCR) was performed to amplify 139 bp of exon 2 in KRAS using specific primers (kindly donated by Dr. Laurent-Puig's laboratory) and under PCR conditions described previously [15]. PCR primer sequences/conditions are available upon request. The efficiency and quality of the amplification PCR were confirmed by running the PCR products on a 2% agarose gel. A negative control containing all the components of the PCR except the template was included in each PCR reaction. DNA Amplified products were purified using a QuickStep TM 2 96-Well PCR Purification Kit (Edge BioSystems, Gaithersburg, MD), according to the manufacturer's instructions. Amplification products were bidirectionally sequenced via the fluorescence dye terminator method in a multi-capillary DNA sequencer using the services of the scientific park of Madrid (Madrid, Spain). Presence of mutation was accepted when it chromatographic peak height was 25% or higher the peak of the wild type reference.
###end p 45
###begin title 46
Statistical Analyses
###end title 46
###begin p 47
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Fisher's exact test was used to examine the association between KRAS mutational status and various clinicopathological features. Concordance between the primary tumor and related metastases was analysed using the kappa index, and discordance was analysed using the McNemar test of symmetry. Disease-free survival and overall survival analyses were calculated according to the Kaplan Meier method, and survival curves were compared using the log-rank test. Disease-free survival was defined as the time from surgical resection of the metastases until the time of documented tumor progression or death. A Cox proportional hazards multivariate regression analysis was performed. P<0.05 was considered significant. Statistical analyses were performed using SPSS version 12.0 (Chicago, IL, USA).
###end p 47
###begin p 48
We thank Esther Diaz and Maria de Miguel for expert technical assistance.
###end p 48
###begin title 49
References
###end title 49
###begin article-title 50
Cancer statistics, 2008.
###end article-title 50
###begin article-title 51
Colorectal metastasis (liver and lung).
###end article-title 51
###begin article-title 52
Liver resection for colorectal metastases.
###end article-title 52
###begin article-title 53
The epidermal growth factor receptor as a target for colorectal cancer therapy.
###end article-title 53
###begin article-title 54
Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
###end article-title 54
###begin article-title 55
Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis.
###end article-title 55
###begin article-title 56
###xml 55 60 <span type="species:ncbi:9606">human</span>
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.
###end article-title 56
###begin article-title 57
ras genes.
###end article-title 57
###begin article-title 58
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.
###end article-title 58
###begin article-title 59
Genetic alterations during colorectal-tumor development.
###end article-title 59
###begin article-title 60
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.
###end article-title 60
###begin article-title 61
###xml 59 67 <span type="species:ncbi:9606">patients</span>
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
###end article-title 61
###begin article-title 62
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
###end article-title 62
###begin article-title 63
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
###end article-title 63
###begin article-title 64
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
###end article-title 64
###begin article-title 65
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.
###end article-title 65
###begin article-title 66
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
###end article-title 66
###begin article-title 67
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.
###end article-title 67
###begin article-title 68
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.
###end article-title 68
###begin article-title 69
Lung metastases from colorectal cancer: surgical resection and prognostic factors.
###end article-title 69
###begin article-title 70
###xml 58 63 <span type="species:ncbi:9606">human</span>
Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver.
###end article-title 70
###begin p 71
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 71
###begin p 72
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work received grant support from Amgen, Red Tematica de Investigacion Cooperativa en Cancer (RTICC, RD06-0020-1022), Fundacion Mutua Madrilena and from Fundacion para la Investigacion Biomedica del Hospital Universitario La Paz (FIBHULP), Madrid, Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 72

